A German-Romanian team gave aged female rats intermittent, low-dose chloroquine, the century-old antimalarial, and watched the treated animals outlive their untreated cage-mates. The drug lifted median lifespan by roughly 10 percent and pushed the longest-lived animals well past controls, while trimming LDL cholesterol, remodeling the IGF growth-hormone axis, keeping body temperature stable into old age, and cutting the benign mammary tumors that usually plague this strain. The twist is mechanistic: chloroquine blocks autophagy, the cellular self-cleaning process nearly every longevity theory says you want to boost, not inhibit. The animals also ate about 10 to 12 percent less food, so part of the benefit may simply be mild calorie restriction rather than the drug itself. The authors did no molecular mechanism work here, so the findings are physiological and hypothesis-generating, not a mechanistic proof.
For thirty years the longevity field has treated autophagy, the process by which cells digest and recycle their own worn-out parts, as sacred. Rapamycin, spermidine, fasting and exercise are all celebrated partly because they switch it on. So it is genuinely awkward that chloroquine, a drug that does the opposite by jamming the lysosome and blocking autophagy, keeps showing up as a lifespan extender.
In this study, researchers at the University of Duisburg-Essen and collaborators in Romania and the UK took 80 middle-aged female Sprague-Dawley rats and split them evenly. Half received chloroquine baked into their food at 10 mg/kg/day on a deliberately intermittent schedule, three weeks on and one week off, tapering to one week on and one week off for the rest of their lives. The cycling was designed to capture the drug’s benefits while dodging the toxicity that continuous dosing had produced in earlier pilot work.
The treated rats lived longer. Median survival rose from about 950 days to about 1050 days, and the log-rank test was convincingly significant. The survival curves split after roughly six months and never rejoined. Along the way the treated animals looked and functioned better: glossier fur, less late-life weight gain, and, strikingly, no evening collapse in body temperature, a marker of the failing hypothalamic thermostat seen in aging controls.
The blood work tells a coherent story. Treated rats showed higher HDL, lower LDL and a better LDL/HDL ratio, without the liver or kidney damage chloroquine can cause at higher doses. The IGF-1 growth axis moved in a sophisticated, two-phase pattern: an early anabolic boost to support tissue maintenance, followed by late-life growth restraint of the kind associated with lower cancer risk. Fittingly, the treated rats had far fewer of the proliferative mammary lesions that dominate this strain’s old age.
The big idea is that a cheap, off-patent, orally available drug may reproduce a slice of what calorie restriction does, without demanding a lifetime of dieting. The caution is equally large. The rats ate less, so this may be partly starvation by another name, no mechanism was measured, no drug levels were confirmed, and a single dose in a single sex of a single strain cannot tell us what happens in humans.
Insights
There is nothing here a person should act on directly. This is a rat study of a prescription drug with a real toxicity profile including irreversible retinal damage, and no human longevity dosing protocol exists as of yet. The extractable signals and their magnitudes are as follows.
Lifespan: median survival rose about 100 days on a 950-day baseline, an effect size near 10.5 percent. The authors headline a 19 percent maximum-lifespan gain, though the raw maxima they report (1271 vs 969 days) actually work out to roughly 31 percent, an internal inconsistency worth noting.
Calorie restriction, unintentionally: the treated rats ate 10 to 12 percent less (roughly 24 vs 27 g/day). The real-world lesson is the boring one that keeps winning, namely that a sustained modest reduction in food intake tracks with better lipids, less weight gain and longer life. This is achievable in humans without any drug.
Lipids: the direction of travel (higher HDL, lower LDL/HDL ratio) mirrors what is targeted clinically for cardiometabolic risk. Magnitude cannot be quantified because the paper reports significance but not the underlying numbers.
Growth signaling: the late-life drop in IGF-1 signaling is the same lever that fasting and protein moderation pull in humans, and is the most translatable concept here even if the drug is not.
Context and Source
- Open access paper: Intermittent Chloroquine Treatment Extends Lifespan and Prevents Mammary Hyperplasia in Female Rats While Reducing Serum LDL and IGFBP3 Levels.
- Institutions: University of Duisburg-Essen and University Hospital Essen (Germany); University of Giessen and University of Marburg (Germany); University Medical Center Gottingen (Germany); University of Medicine and Pharmacy of Craiova (Romania); Ravan Bio Ltd (Manchester, UK).
- Countries: Germany, Romania, United Kingdom.